Oncolytics says phase 1 results of Reolysin as cancer treatment look promising

By E. Janene Geiss

Philadelphia, Jan. 24 - Oncolytics Biotech Inc. announced Tuesday that preliminary results of its phase 1 combination Reolysin/radiation clinical trial was well-tolerated and demonstrated activity in tumors.

The results will be presented at the American Association of Cancer Researchers annual meeting to be held the first week of April in Washington, D.C.

The company's researchers have demonstrated that Reolysin, a reovirus, is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, bladder, prostate, pancreatic and brain tumors. It also has demonstrated successful cancer treatment results in a number of animal models.

Oncolytics is a Calgary, Alta., biotechnology company focused on the development of Reolysin, its proprietary formulation of the human reovirus, as a potential cancer therapeutic.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.